Eli Lilly and Company
LLY
$1188.72
+2.70%
Eli Lilly and Company is a global pharmaceutical firm focused on neuroscience, cardiometabolic health, oncology, and immunology, with flagship products including Mounjaro and Zepbound for diabetes and obesity, Verzenio and Jaypirca in oncology, and Taltz and Olumiant in immunology. As one of the largest drug manufacturers in the world by market capitalization, Lilly has cemented itself as the dominant platform in the GLP-1 and incretin-based obesity and diabetes market, a position reinforced by its deep pipeline and manufacturing scale. The current investor narrative centers on the company's extraordinary growth trajectory — Q2 2026 revenue surged 47.7% year-over-year to $22.97 billion — driven overwhelmingly by cardiometabolic health products, which generated $18.35 billion in segment revenue. Recent news highlights both the promise and the competitive tension in this space: Lilly's retatrutide delivered unprecedented Phase 3 weight-loss results (over half of patients losing 20% of body weight), while rivals such as Novo Nordisk, Viking Therapeutics, and Roche advance their own obesity candidates, keeping the competitive landscape dynamic and the stock's valuation debate intense.…
LLY
Eli Lilly and Company
$1188.72
Related headlines
Investment Opinion: Should I buy LLY Today?
The synthesized recommendation is Buy, with a one-sentence thesis: Eli Lilly's dominant position in the high-growth GLP-1 market, coupled with explosive revenue growth and expanding margins, justifies a premium valuation and offers attractive upside. The analyst consensus is Buy (mean 1.63) with an average target price of $1,328.83, implying 16.3% upside from the current price of $1,142.85.\n\nSupporting evidence includes: 1) Revenue growth of 47.7% YoY in Q2 2026, far exceeding the industry average of low-single digits; 2) Gross margin of 85.8% and operating margin of 54.2%, demonstrating strong pricing power and operating leverage; 3) A forward PE of 24.1x, which is a 48% discount to the trailing PE of 46.6x, and a PEG ratio of 0.48, suggesting undervaluation relative to growth; 4) Free cash flow of $20.05 billion TTM, providing ample resources for investment and dividends.\n\nKey risks that could invalidate the thesis include: 1) Competitive threats from Novo Nordisk, Viking, and Roche eroding market share; 2) Valuation compression if growth slows or earnings disappoint; 3) Regulatory headwinds such as drug pricing reforms. The rating would upgrade to Strong Buy if the stock pulls back to the $1,000 level while maintaining growth, or downgrade to Hold if revenue growth decelerates below 20% or if competitive losses become evident. Relative to its history and peers, the stock is fairly valued to slightly undervalued on a forward basis, but carries a premium on trailing metrics.
Sign up to view all
LLY 12-Month Price Forecast
Eli Lilly presents a compelling growth story with strong fundamentals and a dominant market position. The stock's premium valuation is justified by its exceptional growth trajectory and margin expansion, and the forward PE suggests reasonable valuation if earnings double as expected. However, competitive threats and recent momentum loss warrant caution. I would upgrade to high confidence if the stock breaks above $1,292.65 (52-week high) on strong volume, and downgrade to neutral if revenue growth falls below 30% or if competitive losses become evident.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1329.21 and implied upside of +11.8% versus the current price.
Average Target
$1329.21
0 analysts
Implied Upside
+11.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$930 - $1600
Analyst target range
Analyst coverage is robust, with 29 analysts following Eli Lilly, and sentiment is decisively bullish. The consensus recommendation is "Buy" with a recommendation mean of 1.63 (on a scale where 1.0 is Strong Buy and 5.0 is Strong Sell), and the average price target of $1,328.83 implies approximately 16.3% upside from the current price of $1,142.85. This bullish consensus is reinforced by recent institutional ratings: JP Morgan, TD Cowen, Guggenheim, Truist, Cantor Fitzgerald, Wells Fargo, Citigroup, Bernstein, and UBS all maintain Buy or Overweight-equivalent ratings, with only HSBC holding a "Reduce" rating — a lone bearish voice in an otherwise overwhelmingly positive analyst community.
The target price range is wide, spanning from a low of $930 to a high of $1,600, a spread of $670 (or 72% of the low target), which signals meaningful disagreement about the company's trajectory. The high target of $1,600 implies roughly 40% upside and likely assumes continued blockbuster GLP-1 growth, successful pipeline readouts (such as retatrutide), and sustained multiple expansion. The low target of $930 — about 18.6% below the current price — likely prices in competitive share loss, pricing pressure, or pipeline disappointments. The wide spread reflects genuine uncertainty about the durability of Lilly's obesity franchise in an increasingly crowded market, though the skew toward Buy ratings and the fact that even the low target is not catastrophically below current levels suggests analysts see limited downside relative to the substantial upside potential.
Bulls vs Bears: LLY Investment Factors
The bull case for Eli Lilly is compelling, anchored by explosive revenue growth of 47.7% YoY, expanding margins, and a dominant position in the high-growth GLP-1 market. The bear case centers on a premium valuation that leaves little room for error, recent momentum loss, and rising competition from Novo Nordisk, Viking, and Roche. Currently, the bull evidence is stronger, supported by robust financial performance, a low PEG ratio of 0.48, and overwhelming analyst optimism with a Buy consensus and 16.3% average upside. The single most important tension is whether Lilly can sustain its growth trajectory and justify its premium multiple in the face of intensifying competition; if growth decelerates or competitive threats materialize, the stock could face significant multiple compression.
Bullish
- Explosive revenue growth: Q2 2026 revenue surged 47.7% YoY to $22.97 billion, with a consistent upward stair-step from $12.73B in Q1'25 to $22.97B in Q2'26. This acceleration is driven by cardiometabolic health products, which generated $18.35 billion in the quarter.
- Exceptional profitability and margin expansion: Gross margin reached 85.8% in Q2 2026, up from 84.3% a year ago, while operating margin expanded to 54.2% from 45.1%. Net income was $7.10 billion, a 30.9% net margin, demonstrating strong operating leverage.
- Attractive PEG ratio: The PEG ratio of 0.48 is well below 1.0, suggesting the stock is undervalued relative to its growth rate. The forward PE of 24.1x is a 48% compression from the trailing PE of 46.6x, implying expected earnings doubling.
- Strong analyst consensus and upside: 29 analysts rate the stock a Buy with a mean recommendation of 1.63. The average price target of $1,328.83 implies 16.3% upside from the current price of $1,142.85, with a high target of $1,600 (40% upside).
Bearish
- Premium valuation versus peers: The trailing PE of 46.6x and forward PE of 24.1x are significantly above the industry average of 15-20x forward earnings. The price-to-sales ratio of 14.8x and EV/EBITDA of 31.6x also reflect a substantial premium, leaving little margin for error.
- Recent underperformance and momentum loss: The stock is down 1.5% over the past month and 5.9% over three months, underperforming SPY by 2.1 and 9.2 percentage points, respectively. This divergence suggests profit-taking and a potential mean-reversion phase.
- Elevated leverage and aggressive spending: Debt-to-equity is 1.60 and total-debt-to-capitalization is 61.8%. Capital expenditures of $2.93 billion and acquisitions of $8.75 billion in Q2 2026 indicate heavy investment, which could strain the balance sheet if growth slows.
- Intensifying competition: Novo Nordisk's oral Wegovy shows real-world weight loss, Viking Therapeutics' VK2735 has impressive maintenance data, and Roche's enicepatide has promising Phase 2 results. These threats could erode Lilly's market share and pricing power.
LLY Technical Analysis
Eli Lilly is in a sustained longer-term uptrend that has recently entered a corrective consolidation phase. Over the trailing 12 months, the stock has gained 39.4%, materially outpacing the S&P 500's 15.0% advance, yet the current price of $1,142.85 sits roughly 11.6% below its 52-week high of $1,292.65 and about 45.8% above its 52-week low of $783.85 — placing it at approximately 69.5% of its 52-week range. This positioning suggests the stock retains a constructive long-term trend but is digesting gains rather than pressing to new highs, a classic mid-cycle pause rather than a breakdown. The 23.3% maximum drawdown underscores that even in a powerful uptrend, Lilly is capable of sharp pullbacks that test investor conviction.
Short-term momentum has clearly decelerated and diverges from the strong 1-year trend. The stock is down 1.5% over the past month and 5.9% over the past three months, a stark contrast to the 22.2% gain over six months and 39.4% over one year, signaling that the pace of appreciation has cooled considerably in the second half of 2026. Relative strength metrics confirm this softening: LLY has underperformed SPY by 2.1 percentage points over one month and by a notable 9.2 percentage points over three months, though it still leads by 24.4 points over the full year. This divergence between robust annual performance and recent underperformance suggests a mean-reversion phase or profit-taking consolidation, and with a beta of just 0.502, the stock's recent weakness is not being driven by broad market volatility but by stock-specific dynamics.
Key technical levels are well-defined by the 52-week range. Immediate support rests near the $1,115-$1,120 zone (recent September lows), with stronger structural support at the $1,050-$1,080 area and the 52-week low of $783.85 representing the ultimate downside floor. Resistance is anchored at the 52-week high of $1,292.65, and a decisive breakout above that level would signal renewed momentum and likely invite trend-following capital. Conversely, a breakdown below $1,115 would raise the risk of a deeper retracement toward the $1,000 psychological level. With a beta of 0.502 — roughly half the market's volatility — Lilly is a defensive-growth holding, meaning position sizing can be more aggressive than for high-beta names, but the low beta also implies the stock will not deliver outsized upside simply from market beta alone.
Beta
0.45
0.45x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$784-$1293
Price range past year
Annual Return
+40.9%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | +0.9% |
| 3m | -2.3% | +3.4% |
| 6m | +26.5% | +14.4% |
| 1y | +40.9% | +16.2% |
| ytd | +10.0% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Lilly's revenue trajectory is nothing short of exceptional and, critically, still accelerating. Q2 2026 revenue reached $22.97 billion, up 47.7% year-over-year from $15.56 billion in Q2 2025, and up sequentially from $19.80 billion in Q1 2026 and $19.29 billion in Q4 2025. The multi-quarter progression — $12.73B (Q1'25), $15.56B (Q2'25), $17.60B (Q3'25), $19.29B (Q4'25), $19.80B (Q1'26), $22.97B (Q2'26) — shows a remarkably consistent upward stair-step, with the most recent quarter marking the largest sequential jump. Segment data reveals the engine: Cardiometabolic Health generated $18.35 billion, dwarfing Oncology at $2.57 billion, Immunology at $1.42 billion, and Neuroscience at $429 million, confirming that the GLP-1/incretin franchise is the overwhelming growth driver and that the investment case is fundamentally a bet on continued obesity and diabetes market expansion.
Profitability is robust and margins are expanding at the operating level. Q2 2026 net income was $7.10 billion on a 30.9% net margin, while gross margin reached 85.8% — up from 84.3% in Q2 2025 and 81.9% in Q1 2026 — reflecting favorable product mix and pricing power. Operating margin was 54.2% in Q2 2026, a significant improvement from 45.1% in Q2 2025 and 49.4% in Q1 2026, demonstrating strong operating leverage as revenue scales faster than costs. EBITDA came in at $12.99 billion with a 56.5% EBITDA margin, and the company's trailing net margin of 31.7% and operating margin of 45.6% are exceptional for the pharmaceutical industry, where high R&D spending ($3.82 billion in Q2 2026 alone) typically compresses margins. The company is firmly and increasingly profitable, with EPS of $7.96 in the latest quarter versus $6.30 a year prior.
Balance sheet and cash flow metrics present a more nuanced picture. The debt-to-equity ratio of 1.60 and total-debt-to-capitalization of 61.8% indicate meaningful leverage, though interest coverage of 36.1x (Q2 2026) provides substantial cushion. Free cash flow on a trailing-twelve-month basis is a healthy $20.05 billion, and Q2 2026 free cash flow was $7.76 billion on operating cash flow of $10.69 billion, but capital expenditure of $2.93 billion and acquisitions of $8.75 billion show the company is investing aggressively in capacity and pipeline expansion. ROE is an extraordinary 77.8% and ROA is 20.4%, reflecting highly efficient capital deployment, while the current ratio of 1.58 indicates adequate short-term liquidity. The company generates more than enough cash to fund operations and dividends (payout ratio of 26.1%), but the heavy acquisition and capex spending means it is not purely self-funding its growth ambitions, and the elevated leverage warrants monitoring even as cash generation remains powerful.
Quarterly Revenue
$23.0B
2026-06
Revenue YoY Growth
+47.7%
YoY Comparison
Gross Margin
85.8%
Latest Quarter
Free Cash Flow
$20.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Because Lilly is solidly profitable — Q2 2026 net income of $7.10 billion and trailing EPS positive — the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 46.6x, while the forward PE is 24.1x, a dramatic 48% compression that implies the market expects earnings to roughly double over the next twelve months. This gap is consistent with analyst consensus EPS estimates of $66.89 for the forward period versus the current trailing run-rate, and it signals that investors are pricing in substantial earnings growth driven by continued GLP-1 volume expansion and margin leverage. The PEG ratio of 0.48 — well below 1.0 — suggests that when adjusted for growth, the stock is not expensive, provided that growth materializes.
Relative to the broader Drug Manufacturers - General industry, Lilly trades at a significant premium across most metrics. Its trailing PE of 46.6x and forward PE of 24.1x compare to an industry where large-cap pharma typically trades in the 15-20x forward earnings range, implying a premium of roughly 20-60% depending on the peer set. The price-to-sales ratio of 14.8x and EV/EBITDA of 31.6x are also well above sector norms, reflecting Lilly's superior growth profile — 47.7% revenue growth versus the low-single-digit growth typical of big pharma peers. This premium is justified by Lilly's dominant position in the highest-growth therapeutic category in pharmaceuticals, but it also leaves little margin for error if competitive threats from Novo Nordisk, Viking, or Roche intensify.
Historically, Lilly's valuation has been on a rollercoaster. The trailing PE reached 205x in Q3 2024 (distorted by a temporary earnings trough) and has since normalized to 46.6x, while the price-to-sales ratio has ranged from 32.9x (Q4 2021) to 78.1x (Q1 2024) and now sits at 14.8x on the current data — though this discrepancy reflects differing data vintages. The price-to-book ratio of 36.4x is near the higher end of its historical band (which has ranged from roughly 26x to 61x over the past several years), suggesting the market continues to award a premium multiple. The forward PE of 24.1x, however, is toward the lower end of the stock's recent historical range, implying that if earnings growth delivers as expected, the valuation could prove reasonable or even attractive relative to Lilly's own history.
PE
46.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but noteworthy. The debt-to-equity ratio of 1.60 and total-debt-to-capitalization of 61.8% indicate meaningful leverage, though interest coverage of 36.1x provides a strong cushion. The company's aggressive investment strategy, with $2.93 billion in capital expenditures and $8.75 billion in acquisitions in Q2 2026, could pressure free cash flow if growth slows. Additionally, revenue is heavily concentrated in cardiometabolic health, which accounted for $18.35 billion of $22.97 billion in Q2 2026 revenue; any setback in this segment would disproportionately impact overall performance.\n\nMarket and competitive risks are significant. The stock trades at a premium valuation, with a trailing PE of 46.6x and forward PE of 24.1x, compared to the industry average of 15-20x. This leaves little margin for error, and any earnings miss or competitive threat could trigger multiple compression. The beta of 0.502 indicates lower volatility than the market, but the stock is still susceptible to sector rotation and macro headwinds. Recent news highlights intensifying competition: Novo Nordisk's oral Wegovy, Viking Therapeutics' VK2735, and Roche's enicepatide all pose long-term threats to Lilly's market share. Regulatory risks, such as drug pricing reforms, also loom.\n\nThe worst-case scenario involves a combination of competitive share loss, pipeline disappointments, and pricing pressure, leading to a sharp decline. The 52-week low of $783.85 represents a 31.4% downside from the current price of $1,142.85, while the analyst low target of $930 implies 18.6% downside. A realistic adverse scenario could see the stock retrace to the $930-$950 range, a decline of 17-19%, if growth decelerates and the market re-rates the multiple. In a more severe downturn, the stock could test the 52-week low, resulting in a loss of over 30% from current levels.
FAQ
The key risks include: 1) Competitive risk: Novo Nordisk's oral Wegovy, Viking Therapeutics' VK2735, and Roche's enicepatide could erode Lilly's market share and pricing power, potentially slowing revenue growth. 2) Valuation risk: The stock trades at a premium (trailing PE 46.6x, PS 14.8x), leaving little margin for error; any earnings miss could trigger multiple compression. 3) Financial risk: Debt-to-equity of 1.60 and heavy investment ($8.75B in acquisitions in Q2 2026) could strain the balance sheet if growth slows. 4) Regulatory risk: Drug pricing reforms or adverse policy changes could impact profitability. Ranked by severity, competitive and valuation risks are the most immediate, followed by financial and regulatory risks.
The 12-month forecast includes three scenarios: Bull case (30% probability) targets $1,450-$1,600, assuming continued robust growth and pipeline success; Base case (50% probability) targets $1,250-$1,400, assuming steady growth in line with analyst estimates; Bear case (20% probability) targets $930-$1,000, assuming competitive pressures and multiple compression. The base case is most likely, with a target around the analyst average of $1,328.83, implying 16.3% upside. The key assumption is that revenue growth remains above 30% and margins hold, allowing the forward PE to stabilize around 24-25x. If growth accelerates or pipeline news is positive, the bull case could materialize; if competition intensifies, the bear case could unfold.
LLY's valuation is a mixed picture. On a trailing basis, the PE of 46.6x and PS of 14.8x are significantly above the industry average, suggesting a premium. However, the forward PE of 24.1x is a 48% compression, implying the market expects earnings to double, and the PEG ratio of 0.48 indicates undervaluation relative to growth. Compared to its own history, the forward PE is toward the lower end of its recent range, while the price-to-book of 36.4x is near the higher end. The market is pricing in substantial growth, and if Lilly delivers, the stock could be undervalued; if growth disappoints, the premium multiple could compress. Overall, the stock appears fairly valued to slightly undervalued on a forward basis, but carries a premium on trailing metrics.
From a risk/reward perspective, LLY offers a favorable setup with 16.3% upside to the average analyst target of $1,328.83, and a high target of $1,600 implying 40% upside. The downside risk is moderate, with the analyst low target at $930 (18.6% below current) and the 52-week low at $783.85 (31.4% below). The stock's PEG ratio of 0.48 suggests it is undervalued relative to growth, and the forward PE of 24.1x is reasonable if earnings double as expected. However, the premium valuation and competitive threats mean it is best suited for investors with a long-term horizon and tolerance for volatility. For those seeking growth exposure in healthcare, LLY is a good buy at current levels, but position sizing should account for potential drawdowns.
LLY is best suited for long-term investment due to its strong growth trajectory, deep pipeline, and dominant market position. The stock's beta of 0.502 indicates lower volatility than the market, making it a defensive-growth holding. However, recent momentum has been negative (down 5.9% over three months), so short-term trading could be risky. The company pays a modest dividend (yield 0.56%) and has a payout ratio of 26.1%, indicating a focus on growth over income. Earnings visibility is high given the predictable GLP-1 demand, but competitive threats introduce uncertainty. A suggested minimum holding period is 2-3 years to allow for pipeline readouts and market expansion. Short-term traders might find opportunities around earnings or clinical data releases, but the stock is more suitable for buy-and-hold investors.